Related references
Note: Only part of the references are listed.High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma
Yu Sun et al.
CANCER LETTERS (2018)
Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
Aurelia Lamanuzzi et al.
Oncotarget (2018)
The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma
Nicholas Burwick et al.
LEUKEMIA RESEARCH (2017)
CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
Chang-Xin Shi et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
C. Pawlyn et al.
BLOOD CANCER JOURNAL (2017)
A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
A. K. Mitra et al.
BLOOD CANCER JOURNAL (2017)
Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers
Markus Schick et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Myeloma today: Disease definitions and treatment advances
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
Paul G. Richardson et al.
BLOOD (2016)
Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma
R. H. Prabhala et al.
LEUKEMIA (2016)
Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors
A. K. Mitra et al.
LEUKEMIA (2016)
miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF
Benping Zhang et al.
CURRENT CANCER DRUG TARGETS (2016)
Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease
Liza Shrestha et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2016)
Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma
Li Zhang et al.
ONCOTARGET (2016)
Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming
Irene Riz et al.
ONCOTARGET (2016)
When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response
Shardule P. Shah et al.
MOLECULAR CANCER RESEARCH (2015)
Causal analysis approaches in Ingenuity Pathway Analysis
Andreas Kraemer et al.
BIOINFORMATICS (2014)
microRNAs in the tumor microenvironment: solving the riddle for a better diagnostics
Kishore B. Challagundla et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels
Paul Geeleher et al.
PLOS ONE (2014)
Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Holly A. F. Stessman et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Chaperone machines for protein folding, unfolding and disaggregation
Helen Saibil
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma
Naoya Mimura et al.
BLOOD (2012)
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
John D. Shaughnessy et al.
BLOOD (2011)
Potential role of heat shock proteins in neural differentiation of murine embryonal carcinoma stem cells (P19)
Elahe Afzal et al.
CELL BIOLOGY INTERNATIONAL (2011)
Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma
Marc A. Weniger et al.
CLINICAL CANCER RESEARCH (2011)
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
Dharminder Chauhan et al.
CLINICAL CANCER RESEARCH (2011)
Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma
Constantine S. Mitsiades et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular chaperones in protein folding and proteostasis
F. Ulrich Hartl et al.
NATURE (2011)
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
Rao H. Prabhala et al.
BLOOD (2010)
Investigation of the eIF2α phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells
Azmi Yerlikaya et al.
MOLECULAR BIOLOGY (2010)
Inhibition of eIF2α Dephosphorylation Maximizes Bortezomib Efficiency and Eliminates Quiescent Multiple Myeloma Cells Surviving Proteasome Inhibitor Therapy
Denis M. Schewe et al.
CANCER RESEARCH (2009)
Many facets of bortezomib resistance/susceptibility
Shaji Kumar et al.
BLOOD (2008)
STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival
Manik Chatterjee et al.
BLOOD (2007)
The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype
PA Croonquist et al.
ONCOGENE (2005)
Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice
WC Cheung et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Heat shock proteins in mammalian development
ES Christians et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2003)
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
N Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Heat shock protein 90 homeostasis controls stage differentiation in Leishmania donovani
M Wiesgigl et al.
MOLECULAR BIOLOGY OF THE CELL (2001)
Share Paper
